Evolent Health, Inc (NYSE:EVH) Stock Has Consensus Target Price of $5.96

08 Nov 2026, 06:01 by Teresa Graham · The Cerbat Gem

Evolent Health, Inc (NYSE:EVH – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $6.11.

Several equities analysts have recently issued reports on EVH shares. Citigroup raised shares of Evolent Health from a “neutral” rating to a “buy” rating and reduced their price target for the company from $6.75 to $6.00 in a report on Monday, August 10th. Oppenheimer increased their price objective on shares of Evolent Health from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday. TD Cowen increased their price objective on shares of Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Canaccord Genuity Group cut their price objective on shares of Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Truist Financial reduced their target price on shares of Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th.

Get Our Latest Report on Evolent Health

Insider Activity at Evolent Health

In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total value of $329,460.00. Following the sale, the president owned 655,133 shares in the company, valued at approximately $3,275,665. This trade represents a 9.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.48% of the company’s stock.

Hedge Funds Weigh In On Evolent Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in Evolent Health during the 1st quarter valued at $26,000. Sequoia Financial Advisors LLC acquired a new position in Evolent Health during the 2nd quarter worth $78,000. Royal Bank of Canada grew its stake in shares of Evolent Health by 51.6% in the first quarter. Royal Bank of Canada now owns 25,161 shares of the technology company’s stock worth $57,000 after purchasing an additional 8,563 shares in the last quarter. WINTON GROUP Ltd grew its stake in shares of Evolent Health by 29.6% in the second quarter. WINTON GROUP Ltd now owns 26,700 shares of the technology company’s stock worth $145,000 after purchasing an additional 6,100 shares in the last quarter. Finally, Wealthfront Advisers LLC grew its stake in shares of Evolent Health by 40.8% in the first quarter. Wealthfront Advisers LLC now owns 28,083 shares of the technology company’s stock worth $64,000 after purchasing an additional 8,136 shares in the last quarter.

Key Stories Impacting Evolent Health

Here are the key news stories impacting Evolent Health this week:

Positive Sentiment: Oppenheimer raised its price target to $7 from $6 and maintained an “outperform” rating, implying substantial upside from the cited $4.61 share price. Oppenheimer recommendations
Positive Sentiment: Needham & Company lifted its target to $6 from $5 and kept a “buy” rating, adding to the favorable analyst outlook. Needham recommendations
Positive Sentiment: EVH forecast fiscal 2026 revenue of $2.6 billion to $2.7 billion, with the top of the range above analysts’ $2.6 billion consensus. Third-quarter results and outlook
Neutral Sentiment: Third-quarter adjusted earnings were $0.06 per share, matching estimates and improving from $0.05 a year earlier. Revenue rose 51.3% year over year to $725.37 million, but was slightly below the $727.06 million consensus. Third-quarter results
Negative Sentiment: The reported quarter included a negative net margin of 24.08% and negative return on equity, highlighting that profitability remains a concern despite revenue growth and per-share earnings. Third-quarter results

Evolent Health Stock Up 1.4%

Shares of Evolent Health stock opened at $4.61 on Friday. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52. The business’s 50 day simple moving average is $4.17 and its 200-day simple moving average is $3.88. The stock has a market capitalization of $520.64 million, a price-to-earnings ratio of -1.01 and a beta of 1.03. Evolent Health has a twelve month low of $2.10 and a twelve month high of $6.28.

Evolent Health (NYSE:EVH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. Evolent Health had a negative return on equity of 5.98% and a negative net margin of 21.67%. The business had revenue of $725.37 million for the quarter, compared to the consensus estimate of $727.06 million. During the same quarter last year, the business posted $0.05 EPS. The business’s revenue was up 51.3% on a year-over-year basis. Equities research analysts forecast that Evolent Health will post -0.25 earnings per share for the current year.

About Evolent Health

(Get Free Report)

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.